TBP Bio Group Secures $300 Million Strategic Investment Led by GIC and Platinum Orchid

Taibang Biological Group (formerly listed on Nasdaq under the ticker symbol “CBPO”) has recently reached a financing agreement with multiple investors and formally executed the transaction documents. This round of financing totals USD 300 million, led by Platinum Orchid, a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA), and the Government of Singapore Investment Corporation (GIC), with participation from China Life Capital Investment Limited and Cinda Kunpeng as co-investors.

This financing round marks Taibang Biological Group’s first fundraising since completing its privatization transaction in April 2021, led by a consortium headed by Hony Capital. The round has garnered strong support from top-tier investors both domestically and internationally, reflecting the capital market’s high recognition of Taibang Biological Group’s ability to create value for shareholders and patients, as well as its growth potential.

Upon completion of the financing, Taibang Biological Group’s capital structure will be further optimized, facilitating a stronger foothold in the domestic market. The company will secure more robust and extensive resource support in areas such as plasma station expansion and new product R&D, thereby enabling faster and healthier growth within China’s vast market landscape.

Centurium Capital first invested in Taibang Biological Group in 2018 and is its largest institutional shareholder. Healthcare is one of Centurium Capital’s key investment focuses, with a diversified and flexible approach to its healthcare investment portfolio that encompasses both direct investments in growth-stage companies and controlling-stake transactions. Leveraging the team’s deep industry insights accumulated over many years and their judgment on macroeconomic trends, Centurium Capital adheres to an investment philosophy centered on operational improvement and value creation. It has continued to expand its footprint in the healthcare sector, completing investments in multiple healthcare projects to date.

Taibang Biological Group was established in 2002 as an advanced, integrated enterprise specializing in blood products and biopharmaceuticals. Its core business encompasses the research and development, production, and sales of blood-derived and biological products. The Group operates a blood products manufacturing base that adheres to advanced technical standards, boasts a high-caliber R&D team and dedicated laboratories for blood product development, and maintains a comprehensive product portfolio. This portfolio covers three major categories—albumin, immunoglobulins, and coagulation factors—comprising 10 approved product types and more than 20 specifications.

In addition, the Group’s non-blood product business segment operates multiple production lines for products such as placental polypeptides, artificial dura mater, artificial spinal dura mater, artificial nerve sheath conduits, and fasciae, as well as the full range of neurosurgical products under the German Zeppelin brand. Its products cover the majority of provincial-level medical markets across mainland China.

Abu Dhabi Investment Authority (ADIA), established in 1976, is a globally diversified investment institution that undertakes prudent investments on behalf of the Abu Dhabi Government, with a focus on creating long-term value.

GIC, established in 1981, is one of the world’s leading investment companies, dedicated to building a stable and prosperous financial future for Singapore. As the manager of Singapore’s foreign reserves, GIC adopts a long-term, disciplined investment approach and employs diverse strategies to leverage its unique advantages in investing broadly across global asset classes, including equities, fixed income, real estate, private equity, venture capital, and infrastructure. As a long-term value investor, GIC serves as a trusted partner through its diversified asset allocation capabilities and global connectivity. GIC strives to add significant value to its investments. Headquartered in Singapore, GIC maintains offices in eleven major financial centers worldwide, with a talent pool of over 1,900 professionals and an investment footprint spanning more than 40 countries.

China Life Capital Investment Limited is a specialized private equity investment platform under China Life. Adhering to the investment philosophy of “investing in the future, investing in innovation, and investing in value,” China Life Capital leverages the professional advantages of insurance funds and China Life’s sense of responsibility to serve national strategies, support the real economy, and demonstrate China Life’s commitment and impact.

China Life Health Fund, initiated and established by China Life Capital Investment Limited, is a leading flagship healthcare industry investment fund in China. Since its inception, the fund has achieved extensive investment coverage across life sciences, medical technology, healthcare services, and digital health, investing in a portfolio of leading enterprises in China’s healthcare sector.

Cinda Kunpeng (Shenzhen) Equity Investment Management Co., Ltd. (hereinafter referred to as “Cinda Kunpeng”) was established in April 2019. It is an investment management institution specializing in mergers, acquisitions, and restructuring, with a strategic focus on emerging industries in the Guangdong-Hong Kong-Macao Greater Bay Area, creating value through industrial empowerment. Cinda Kunpeng is primarily engaged in M&A/restructuring and equity investment activities related to listed companies and companies preparing for initial public offerings, providing enterprises with essential development capital and facilitating the acquisition of high-quality assets within their industries.